Efficacy
After a median observation of 65.4 months (interquartile range [IQR] 52.6–69.4 months) and a median off-treatment duration of 54.6 months, patients in the Ven-Obi arm had a significantly longer PFS than patients in the Clb-Obi arm (Hazard ratio [HR] 0.35 [95% CI 0.26–0.46], 